Hua Medicine Announces 2023 Interim Results
Hua Medicine Announces 2023 Interim Results
Stay updated with breaking news from Li Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Hua Medicine Announces 2023 Interim Results
-- First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. Since the launch of commercial sales at the end of October 2022 to June 30, 2023, HuaTangNing achieved a total sales revenue of RMB87.9 million. For the first half of 2023, approximately 212,000 boxes of HuaTangNing were sold, and Hua Medicine achieved revenues of RMB70.3 million, representing approximately a 299.6% increase in revenue compared with the second half of 2022.
NEW YORK, Aug. 22, 2023 -- SunCar Technology Group Inc. , a leading provider of digitalized enterprise automotive after-sales services and online auto insurance intermediation service in China,...
The energy company slated to build a factory near a Michigan military installation is registered as a Chinese foreign principal, according to DOJ records.
LAHORE: Optimistic about the huge advantages of Pakistan’s textile industry, Challenge Fashion (Pvt.) Ltd is...